Boffard, 200517
| 143 blunt trauma patients requiring >6 units of blood | Three doses of intravenous rFVIIa or placebo, 200 μg/kg, 100 μg/kg, 100 μg/kg at time zero, 1 h and 3 h | Randomised, blinded placebo-controlled trial | Number of units RBCs transfused over next 48 h. Also survival and adverse events | No difference in survival. Reduction in RBC transfusion in rFVIIa group (reduced by 2.6 units) |
|
Boffard, 200517
| 134 penetrating trauma patients requiring >6 units of blood | Three doses of intravenous rFVIIa or placebo, 200 μg/kg, 100 μg/kg, 100 μg/kg at time zero, 1 h and 3 h | Randomised, blinded placebo-controlled trial. | Number of units RBCs transfused over next 48 h. Also survival and adverse events | No difference in survival or any other measured outcome |
|
Hauser, 201018
| 573 trauma patients requiring between 4 and 8 units RBCs in the first 12 h following injury | Three doses of intravenous rFVIIa or placebo, 200 μg/kg, 100 μg/kg, 100 μg/kg at time zero, 1 h and 3 h | Randomised, blinded placebo-controlled trial | 30-day mortality | No difference in mortality between groups. No difference in adverse events | Trial stopped due to lower mortality than predicted in trial study group |